Chronic obstructive pulmonary disease (COPD), an irreversible form of lung disease, is treated with prescription drugs, lifestyle changes, rehabilitation therapies, and surgery in certain cases. The ...

Inhaler misuse leading to inadequate medication delivery impacts a person's ability to manage symptoms of chronic obstructive pulmonary disease (COPD), and additional education about proper ...

The surprisingly affordable AnkerMake M5C open-frame 3D printer is easy to assemble and to use. It has a generous print area for its price, and our testing shows it is capable of high-quality ...

We tested over 50 of the best 3D printers - and these are the units we recommend checking out. Whether you're prototyping or printing miniatures, business or beginner, my hardware team has ...

The rise of the consumer 3D printer has yielded amazing devices for designers, engineers, hobbyists, tinkerers, and schools alike. I've been reviewing 3D printers for PCMag since the first widely ...

More affordable than ever, 3D printers are booming for personal, professional, and educational use. Here's everything to know before you buy one, along with the top models from our hands-on testing.

While his main areas of expertise are maker tools -- 3D printers, vinyl cutters, paper printers, and laser cutters -- he also loves to play board games and tabletop RPGs. Expertise 3D printers ...

Please view our affiliate disclosure. In the rapidly evolving world of technology, artificial intelligence (AI) has been a game-changer, especially in the field of 3D object generation. AI-powered 3D ...

Dupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be controlled with other medications.

Over the last decade, as other companies—such as AstraZeneca with IL-5 inhibitor Fasenra—struggled to advance candidates for COPD, Regeneron and Sanofi took a more “phenotype-driven approach ...

This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

The drug was cleared for use in adults whose COPD symptoms aren’t under control and whose disease is driven by eosinophils, a type of immune cell that can contribute to inflammation. There are ...